Published in Neurology on October 29, 2008
Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance. J Neuroinflammation (2012) 1.52
Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study. BMC Neurol (2009) 0.87
MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients. PLoS One (2014) 0.83
Influence of apolipoprotein E plasma levels and tobacco smoking on the induction of neutralising antibodies to interferon-beta. J Neurol (2010) 0.81
Can we spot the IFNbeta nonresponders? Neurology (2008) 0.75
Safety, Tolerability, and Immunogenicity of Interferons. Pharmaceuticals (Basel) (2010) 0.75
More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia. Atherosclerosis (1999) 1.94
North-South twinning in paediatric haemato-oncology: the La Mascota programme, Nicaragua. Lancet (1998) 1.75
Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler (2006) 1.70
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology (2011) 1.68
Online reference database of European Y-chromosomal short tandem repeat (STR) haplotypes. Forensic Sci Int (2001) 1.67
Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry (2002) 1.64
A diffusion tensor MRI study of cervical cord damage in benign and secondary progressive multiple sclerosis patients. J Neurol Neurosurg Psychiatry (2009) 1.64
Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology (2008) 1.60
Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci (2007) 1.59
Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua. Ann Oncol (1997) 1.58
Elucidating the role of matrix stiffness in 3D cell migration and remodeling. Biophys J (2011) 1.58
Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation (2000) 1.48
In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain (2007) 1.48
Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum (1997) 1.45
A new locus for autosomal dominant nocturnal frontal lobe epilepsy maps to chromosome 1. Neurology (2000) 1.45
A novel Angiogenin gene mutation in a sporadic patient with amyotrophic lateral sclerosis from southern Italy. Neuromuscul Disord (2007) 1.45
Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. J Neurosci (2001) 1.42
Cerebral venous thrombosis and isolated intracranial hypertension without papilledema in CDH. Neurology (2001) 1.42
L-thymidine is phosphorylated by herpes simplex virus type 1 thymidine kinase and inhibits viral growth. J Med Chem (1992) 1.41
Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med (1996) 1.31
Poly(ADP-ribose) polymerase is a B-MYB coactivator. J Biol Chem (2000) 1.29
Differential distribution and modulation of expression of alpha 1/beta 1 integrin on human endothelial cells. J Cell Biol (1991) 1.29
Mitotic signaling by beta-amyloid causes neuronal death. FASEB J (1999) 1.21
In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain (2001) 1.17
Prevalence and drug susceptibility of pathogens causing bloodstream infections in northern Italy: a two-year study in 16 hospitals. Eur J Clin Microbiol Infect Dis (2002) 1.16
Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients. Mult Scler (2009) 1.13
Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. Mult Scler (2013) 1.12
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler (2011) 1.11
Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. J Biol Chem (2000) 1.11
Physical interaction between CDK9 and B-Myb results in suppression of B-Myb gene autoregulation. Oncogene (2000) 1.10
Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. Mult Scler (2006) 1.10
Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology (2005) 1.10
Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods (2001) 1.09
Constitutive expression of B-myb can bypass p53-induced Waf1/Cip1-mediated G1 arrest. Proc Natl Acad Sci U S A (1994) 1.08
Accounting for body size deviations when reporting bone mineral density variables in children. Osteoporos Int (2008) 1.08
Autosomal recessive hereditary motor and sensory neuropathy with focally folded myelin sheaths: clinical, electrophysiologic, and genetic aspects of a large family. Neurology (1996) 1.07
Cognitive impairment and structural brain damage in benign multiple sclerosis. Neurology (2008) 1.06
Coronary-coronary bypass: theoretical basis and techniques. J Cardiovasc Surg (Torino) (1987) 1.06
Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy (2005) 1.06
Lack of enantiospecificity of human 2'-deoxycytidine kinase: relevance for the activation of beta-L-deoxycytidine analogs as antineoplastic and antiviral agents. Mol Pharmacol (1997) 1.05
Ectopic thyroid tissue in the ventricular outflow tract: embryologic implications. Cardiology (1995) 1.04
Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. Mult Scler (2013) 1.03
Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler (2007) 1.03
Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Brain (2006) 1.02
Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry (2004) 1.01
Local adaptation across a climatic gradient despite small effective population size in the rare sapphire rockcress. Proc Biol Sci (2001) 1.01
Refining current knowledge on the yeast FLR1 regulatory network by combined experimental and computational approaches. Mol Biosyst (2010) 1.01
Myocardial revascularization procedures on multisegment diseased left anterior descending artery: endarterectomy or multiple sequential anastomoses (jumping)? Minerva Cardioangiol (1996) 1.00
New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones. J Med Chem (1995) 0.99
Stereospecificity of human DNA polymerases alpha, beta, gamma, delta and epsilon, HIV-reverse transcriptase, HSV-1 DNA polymerase, calf thymus terminal transferase and Escherichia coli DNA polymerase I in recognizing D- and L-thymidine 5'-triphosphate as substrate. Nucleic Acids Res (1995) 0.99
15(S)-HETE modulates LTB(4) production and neutrophil chemotaxis in chronic bronchitis. Am J Physiol Cell Physiol (2000) 0.99
Kinetic studies with N2-phenylguanines and with L-thymidine indicate that herpes simplex virus type-1 thymidine kinase and thymidylate kinase share a common active site. Biochem J (1994) 0.99
MicroRNA 143-145 deficiency impairs vascular function. Int J Immunopathol Pharmacol (2012) 0.98
Study of mediators of anaphylaxis in nasal wash fluids after aspirin and sodium metabisulfite nasal provocation in intolerant rhinitic patients. Ann Allergy (1987) 0.98
Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. Ann Oncol (2002) 0.98
Mediator release after endobronchial antigen challenge in patients with respiratory allergy. J Allergy Clin Immunol (1990) 0.97
Cyclooxygenase-2 and synthesis of PGE2 in human bronchial smooth-muscle cells. Am J Respir Crit Care Med (1997) 0.96
Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology (2003) 0.96
Ca2+ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Death Differ (2005) 0.96
Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology (2004) 0.96
Additional approaches to DNA typing of skeletal remains: the search for "missing" persons killed during the last dictatorship in Argentina. Electrophoresis (1997) 0.95
The fragile X premutation presenting as postprandial hypotension. Neurology (2004) 0.95
Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler (2006) 0.95
Vitamin E deficiency due to chylomicron retention disease in Marinesco-Sjögren syndrome. Ann Neurol (2000) 0.95
[Neurologic manifestations of dissecting aneurysms of the aorta]. Med Clin (Barc) (1989) 0.95
Reoperative cardiac valve surgery: a multivariable analysis of risk factors. Cardiovasc Surg (1994) 0.94
Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread. Oncogene (2009) 0.94
Tramadol anti-inflammatory activity is not related to a direct inhibitory action on prostaglandin endoperoxide synthases. Eur J Pain (2000) 0.94
15-Lipoxygenase expression and 15(S)-hydroxyeicoisatetraenoic acid release and reincorporation in induced sputum of asthmatic subjects. J Allergy Clin Immunol (2000) 0.94
Structural identification of cytochrome P450-dependent arachidonate metabolites formed by rabbit medullary thick ascending limb cells. J Biol Chem (1991) 0.94
Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology (2000) 0.93
Pathological findings in subsynovial connective tissue in idiopathic carpal tunnel syndrome. Clin Neuropathol (2009) 0.93
Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw (2001) 0.92